Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 RBD subunit recombinant protein + alum + CpG 1018
- Development stage
- Unknown
- Lead developer
- Dynavax Technologies
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine comprising a recombinant protein subunit containing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, formulated with alum (aluminum hydroxide) and CpG 1018 as adjuvants. The RBD is a critical segment of the spike protein responsible for binding to the ACE2 receptor on host cells, making it a prime target for neutralizing antibody responses. CpG 1018 is a toll-like receptor 9 (TLR9) agonist that enhances vaccine-induced immunity. This combination is designed to elicit strong humoral and cellular immune responses against SARS-CoV-2, including multiple variants, by focusing immune responses specifically on the highly immunogenic RBD region. Such vaccines are being used or evaluated in multiple settings for the prevention of COVID-19, aiming to improve immunogenicity, breadth, and durability of protection compared to unadjuvanted protein subunits[1][2][4][6].
- Other names
- SARS-CoV-2 recombinant RBD protein vaccine + alum + CpG 1018
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on SARS-CoV-2 RBD subunit recombinant protein + alum + CpG 1018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 RBD subunit recombinant protein + alum + CpG 1018.